1 unchanged sentence
Insider Trading Arrangements
−Removed: On February 3, 2026, John Thomas , our Executive Vice President, General Counsel, and Corporate Secretary , adopted a Rule 10b5-1 trading arrangement (the “Trading Plan”) that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 1,903 shares of our common stock, subject to certain conditions.
−Removed: The end date of the Trading Plan is December 31, 2026 , subject to early termination in accordance with the terms of the Trading Plan, including upon completion of the sale of all of the shares of our common stock subject to the Trading Plan.
−Removed: On March 9, 2026 , Daniel Janney , one of our directors , terminated a Rule 10b5-1 trading arrangement that was originally adopted on November 25, 2025 .
−Removed: The Rule 10b5-1 trading arrangement was terminated during the Company’s unrestricted trading window and at a time when Mr.
−Removed: Janney was not in possession of material, non-public information about the Company.
−Removed: 71,964 shares of our common stock were sold under the Rule 10b5-1 trading arrangement prior to termination of the arrangement.
−Removed: During the three months ended March 31, 2026, other than as set forth above, no other director or officer (as that term is defined by the SEC in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: 10.1 Employment Agreement dated September 1, 2021 , by and between Krystal Biotech, Inc.
−Removed: and John Thomas.
−Removed: 10.2 Employment Agreement dated January 4, 2022 , by and between Krystal Biotech Switzerland, GmbH and Laurent Goux .
+Added: During the three months ended June 30, 2026, no director or officer (as that term is defined by the SEC in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
31.1 Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
3 unchanged sentences
101 Inline XBRL (Extensible Business Reporting Language).
−Removed: The following materials from this Quarterly Report on Form 10-Q for the period ended March 31, 2026, are formatted in Inline XBRL:
+Added: The following materials from this Quarterly Report on Form 10-Q for the period ended June 30, 2026, are formatted in Inline XBRL:
(i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of operations and comprehensive income of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc.
4 unchanged sentences
KRYSTAL BIOTECH, INC.
+Added: August 3, 2026
President and Chief Executive Officer
(Principal executive officer)
+Added: August 3, 2026
/s/ Kathryn A.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.